These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 11932286)

  • 1. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr; 1999 Feb; 134(2):215-21. PubMed ID: 9931532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
    Carrel AL; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
    Höybye C
    Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
    Allen DB; Carrel AL
    J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
    Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
    Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome.
    Höybye C
    Acta Paediatr; 2007 Mar; 96(3):410-3. PubMed ID: 17407467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.
    Myers SE; Whitman BY; Carrel AL; Moerchen V; Bekx MT; Allen DB
    Am J Med Genet A; 2007 Mar; 143A(5):443-8. PubMed ID: 17103437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
    Lafortuna CL; Minocci A; Capodaglio P; Gondoni LA; Sartorio A; Vismara L; Rizzo G; Grugni G
    J Clin Endocrinol Metab; 2014 May; 99(5):1816-24. PubMed ID: 24471571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome.
    L'Allemand D; Eiholzer U; Schlumpf M; Torresani T; Girard J
    Horm Res; 2003; 59(5):239-48. PubMed ID: 12714788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
    Höybye C; Hilding A; Jacobsson H; Thorén M
    Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
    Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.